Germany· DE-A57-218561869b4ca99f
Vorteza
A medicinal product containing bortezomib, registered in Germany by Demo Abee.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Bortezomib
- Manufacturer
- Demo Abee
- Country
- Germany (DE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Bortezomib in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainBORTEZOMIB ACCORD 1 MG POLVO PARA SOLUCION INYECTABLE EFGAccord Healthcare S.L.U.
- NetherlandsBortezomib Accord 1 mg, poeder voor oplossing voor injectieAccord Healthcare S.L.U.
- FinlandBortezomib AccordAccord Healthcare S.L.U.
- United StatesbortezomibHikma Pharmaceuticals USA Inc.
- United KingdomBortezomib 1.6mg/0.64ml in Sodium chloride 0.9% solution for injection pre-filled syringesSpecial Order
- PolandBortezomib AccordAccord Healthcare S.L.U.
- SwedenBortezomib Accord 1 mg Pulver till injektionsvätska, lösningAccord Healthcare S.L.U.
- CzechiaBORTEZOMIB ACCORDAccord Healthcare S.L.U., Barcelona
Authorised across Europe · EMA
The same active substance is authorised in 28 EEA countries. Names it is sold under:
- Austria · Abormib, Bortezomib Ever Pharma
- Belgium · Bortezomib Eg, Bortezomib Eugia
- Bulgaria · Bortezomib Ever Pharma, Бортезомиб Актавис
- Cyprus · Bortezomib Pharmazac, Bortezomib Stada
- Czechia · Bortezomib Ever Pharma, Bortezomib Msn
- Denmark · Bortezomib Actavis, Bortezomib Ever Pharma
- Spain · Bortezomib Aurovitas, Bortezomib Combix
- Finland · Bortezomib Avansor, Bortezomib Ever Pharma
- France · Bortezomib, Bortezomib Arrow
- United Kingdom (Northern Ireland) · Bortezomib, Bortezomib Accord
- Greece · Bortezomib Pharmazac, Bortezomib Sandoz
- Croatia · Bortezomib Alpha-Medical, Bortezomib Ever Pharma
- Hungary · Bortezomib Ever Pharma, Bortezomib Msn
- Ireland · Bortezomib Aspire Pharma (Malta), Bortezomib Biotech Pharma Limited
- Iceland · Bortezomib Accord, Bortezomib Actavis
- Italy · Bortezomib Aurobindo, Bortezomib Dr. Reddy’s
- Liechtenstein · Bortezomib Accord, Bortezomib Fresenius Kabi
- Luxembourg · Bortezomib Eg
- Latvia · Bortezomib Tzf
- Malta · Bortezomib Clonmel, Bortezomib Dr. Reddy’s
- Netherlands · Bortezomib Amarox, Bortezomib Cf
- Norway · Bortezomib Accord, Bortezomib Ever Pharma
- Poland · Adabonib, Bortezomib Eugia
- Portugal · Bortezomib Ever Pharma, Bortezomib Extrovis
- Romania · Bortezomib, Bortezomib Dr. Reddy’s
- Sweden · Bortezomib Avansor, Bortezomib Ever Pharma
- Slovenia · Bortezomib Actavis, Bortezomib Ever Pharma
- Slovakia · Bortezomib Ever Pharma, Bortezomib Glenmark
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b3bb3412-d5c3-4d73-bf94-5a8b194625da GET /v1/drugs/b3bb3412-d5c3-4d73-bf94-5a8b194625da?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Intravenous Use ,Subcutaneous Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Bortezomib",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about bortezomib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.